Taking flight: Fanshawe College program soars to meet demand for aircraft mechanics
Norton Wolf School of Aviation and Aerospace Technology seen in London, Ont. on May 21, 2025. (Sean Irvine/CTV News London)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
3 hours ago
- CTV News
Invisible smoke from Canadian wildfires detected over Europe: study
An orange-coloured haze, resulting from a nearby wildfire, is seen on a helipad in La Ronge, Sask., in an undated handout photo. THE CANADIAN PRESS/HO-Saskatchewan Public Safety Agency Invisible smoke from Canadian wildfires has been detected high above Europe. According to a new study from the Leibniz Institute for Tropospheric Research in Germany, layers of invisible smoke were detected in Europe's atmosphere during the 2023 wildfire season. Similar results were observed again in early June. 'This suggests that the atmosphere over Europe might be more polluted than previously thought, especially during the summer wildfire season,' the study explained. Published in the journal Atmospheric Chemistry and Physics, the study was based on lidar measurements in Leibniz, Germany. Short for Light Detection and Ranging, lidar is a remote sensing technology that uses laser light to create three-dimensional models. It works similarly to radar, which uses radio waves. Lidar was able to reveal layers of wildfire smoke that were otherwise invisible on satellite images. 'In the spring and summer of 2023, huge wildfires raged across Canada, with unusual intensity in the provinces of Alberta and British Columbia,' the study said. 'With the prevailing westerly winds, large amounts of biomass-burning aerosol were transported towards Europe.' Researchers say these thin layers of smoke in the atmosphere can contribute to ice cloud formation, impacting sunlight and climate on the ground.
National Post
4 hours ago
- National Post
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic. Article content Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future. Article content 'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.' Article content Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases. Article content 'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.' Article content About Innospera Pharma Article content Article content Article content
National Post
4 hours ago
- National Post
GL CHEMTEC Announces Completion of a New GMP Facility for Advanced Pharmaceutical Materials
Article content OAKVILLE, Ontario — GL CHEMTEC, a leading North American-based CDMO providing advanced chemistry services to the pharmaceutical and biotech sectors, is pleased to announce the completion of our state-of-the-art Good Manufacturing Practice (GMP) Kilo lab facility. This strategic expansion strengthens our commitment to delivering high-quality materials to our valued customers across the pharmaceutical and life science sectors. Article content The new, fully operational Kilo scale GMP facility will serve increased customer demand for advanced materials suitable for use in human clinical trials. This investment enables GL CHEMTEC to bridge the gap between pre-clinical offerings and first-in-human, offering our clients a seamless pathway from concept to clinic and commercialization. Article content 'Our new Kilo lab GMP facility represents a significant milestone in GL CHEMTEC's growth strategy,' said Dr. Gamil Alhakimi, CEO. 'By enhancing our capabilities in material science and drug delivery, we can better serve our customers with faster development cycles, superior quality control, and more efficient scaling processes.' Article content Key features of the new GMP facility: Article content The facility is now fully operational and accepting new projects. Current customers can contact their GL CHEMTEC representative for more information on how this new capability can benefit their existing and future projects. Prospective clients are invited to visit the GL CHEMTEC website to learn more. Article content 'This investment is a further testament to GL CHEMTEC's unwavering commitment to advancing drug development and delivery solutions,' Dr. Alhakimi stated. 'We are now better positioned to support our partners in navigating the complexities of scale-up and clinical trials, ultimately contributing to a healthier future.' Article content About GL CHEMTEC Article content Over the last two decades, GL CHEMTEC has established itself as a leader in the life sciences sector, delivering sustainable, innovative solutions with unparalleled speed and passion. The company's track record of success is rooted in an unwavering commitment to their customers and their unique ability to adapt to diverse needs through a flexible, collaborative approach. Located in North America, GL CHEMTEC provides a secure supply chain, enabling accelerated early-stage API development and the seamless transition of innovative drug delivery solutions from research and development to manufacturing. Article content Article content Article content Article content Article content
